ImmuCell Corporation — Form 8-K Summary
Filing date: October 13, 2026; report date and event date: October 12, 2026. The company’s announcement concerns the third quarter ended September 30, 2026.
Business context and results
ImmuCell reported that preliminary, unaudited product sales increased 46% in the third quarter of 2026 compared with the third quarter of 2025. The 8-K refers to an accompanying press release, but its text is not included in the supplied filing content.
Financial metrics and comparison
The filing provides the percentage change in product sales only. It does not provide a clear dollar value for sales or information on profit, cash flow, margins, debt, liquidity, or other financial metrics. The year-over-year comparison is the reported 46% increase in product sales.
Outlook, risks, and unusual items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are stated in the supplied filing text. Sales results are preliminary and unaudited.
Investor verification points
- Review Exhibit 99.1 for the full press release and any sales figures or additional context.
- Verify final third-quarter results when the company reports complete financial statements.
- Assess whether the sales increase translated into improved profitability and cash flow; this filing does not provide those details.